KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Current Leases (2019 - 2025)

Exact Sciences has reported Current Leases over the past 11 years, most recently at $33.6 million for Q4 2025.

  • Quarterly Current Leases rose 22.63% to $33.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.6 million through Dec 2025, up 22.63% year-over-year, with the annual reading at $33.6 million for FY2025, 22.63% up from the prior year.
  • Current Leases was $33.6 million for Q4 2025 at Exact Sciences, up from $31.9 million in the prior quarter.
  • Over five years, Current Leases peaked at $33.6 million in Q4 2025 and troughed at $15.3 million in Q1 2021.
  • The 5-year median for Current Leases is $27.3 million (2024), against an average of $26.3 million.
  • Year-over-year, Current Leases surged 78.86% in 2021 and then fell 10.59% in 2024.
  • A 5-year view of Current Leases shows it stood at $19.7 million in 2021, then surged by 44.09% to $28.4 million in 2022, then grew by 3.52% to $29.4 million in 2023, then decreased by 6.8% to $27.4 million in 2024, then grew by 22.63% to $33.6 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Current Leases are $33.6 million (Q4 2025), $31.9 million (Q3 2025), and $31.3 million (Q2 2025).